U.S. flag

An official website of the United States government

CYP2C19*24 AND CYP2C19: no function

Germline classification:
drug response (1 submission)
Review status:
4 stars out of maximum of 4 stars
practice guideline
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000783654.10

Alleles description [Variation Report for CYP2C19*24]

NM_000769.4(CYP2C19):c.1197A>G (p.Lys399=)

Gene:
CYP2C19:cytochrome P450 family 2 subfamily C member 19 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
10q23.33
Genomic location:
Preferred name:
NM_000769.4(CYP2C19):c.1197A>G (p.Lys399=)
HGVS:
  • NC_000010.11:g.94849964A>G
  • NG_008384.3:g.92284A>G
  • NM_000769.4:c.1197A>GMANE SELECT
  • NP_000760.1:p.Lys399=
  • NC_000010.10:g.96609721A>G
  • NM_000769.1:c.1197A>G
Links:
dbSNP: rs377184510
NCBI 1000 Genomes Browser:
rs377184510
Molecular consequence:
  • NM_000769.4:c.1197A>G - synonymous variant - [Sequence Ontology: SO:0001819]
Functional consequence:
No function

NM_000769.4(CYP2C19):c.1004G>A (p.Arg335Gln)

Gene:
CYP2C19:cytochrome P450 family 2 subfamily C member 19 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
10q23.33
Genomic location:
Preferred name:
NM_000769.4(CYP2C19):c.1004G>A (p.Arg335Gln)
HGVS:
  • NC_000010.11:g.94842879G>A
  • NG_008384.3:g.85199G>A
  • NM_000769.4:c.1004G>AMANE SELECT
  • NP_000760.1:p.Arg335Gln
  • NC_000010.10:g.96602636G>A
Protein change:
R335Q
Links:
dbSNP: rs118203757
NCBI 1000 Genomes Browser:
rs118203757
Molecular consequence:
  • NM_000769.4:c.1004G>A - missense variant - [Sequence Ontology: SO:0001583]
Functional consequence:
No function

Condition(s)

Name:
CYP2C19: no function
Identifiers:

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000922177Clinical Pharmacogenetics Implementation Consortium
practice guideline

(Clinical Pharmacogenetics Implementation Consortium)
drug response
Condition: CYP2C19: no function
germlinecuration

PubMed (1)
[See all records that cite this PMID]

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlinenot applicablenot providednot providednot providednot providednot providedcuration

Citations

PubMed

CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network.

Relling MV, Klein TE.

Clin Pharmacol Ther. 2011 Mar;89(3):464-7. doi: 10.1038/clpt.2010.279. Epub 2011 Jan 26. No abstract available.

PubMed [citation]
PMID:
21270786
PMCID:
PMC3098762

Details of each submission

From Clinical Pharmacogenetics Implementation Consortium, SCV000922177.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedcuration PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlinenot applicablenot providednot providednot providednot providednot providednot providednot provided

Last Updated: May 26, 2024